Top

Cancer Immunology, Immunotherapy

Published in:

01-10-2020 | Neuroendocrine Tumor | Original Article

Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor

Authors: Valentine Suteau, Alexandre Collin, Philippe Menei, Patrice Rodien, Marie-Christine Rousselet, Claire Briet

Published in: Cancer Immunology, Immunotherapy | Issue 10/2020

Abstract

Objective

To explore the programmed death-ligand 1 (PD-L1) expression in varied subtypes of pituitary neuroendocrine tumors with assessment of their clinical behavior at diagnosis and follow-up.

Methods

We conducted a retrospective monocentric study, including all patients operated in the Academic Hospital of Angers (France) for a pituitary neuroendocrine tumor between 2012 and 2018. PDL-1 immunostaining was performed using a European Conformity—In Vitro Diagnostic-labeled anti-PDL1 antibody (clone 22C3). PD-L1 immunostaining was evaluated as the percentage of tumor cells showing positive membrane staining, into four grades: grade 0 = < 1%, grade 1 = 1 to 5%, grade 2 = 6 to 49% and grade 3 = ≥ 50%. PD-L1 expression was compared with tumor features (secretion, proliferation, invasion) and outcome.

Results

The study included 139 pituitary neuroendocrine tumors, including 84 (60%) nonfunctioning adenomas. Twenty-five pituitary neuroendocrine tumors were PD-L1 positive (18%), including 3 grade 3, 8 grade 2 and 14 grade 1. PD-L1 expression was not different between functioning and nonfunctioning adenomas (p = 0.26). Among 16 tumors with proliferative markers (Ki-67 ≥ 3% and p53 positive), only one was PD-L1 positive.

Conclusion

In our series, PD-L1 was expressed in a rather small proportion of PitNET (18%), and this immune marker was not associated with any biological characteristic or behavior of the pituitary tumors. Thus, PD-L1 staining may be necessary before considering PD-L1 blockage in pituitary neuroendocrine tumors, in case of therapeutic impasse.

Ostrom QT, Gittleman H, Truitt G et al (2018) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-Oncol. https://doi.org/10.1093/neuonc/noy131CrossRefPubMedPubMedCentral

Tampourlou M, Ntali G, Ahmed S et al (2017) Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab 102:1889–1897. https://doi.org/10.1210/jc.2016-4061CrossRefPubMed

Molitch ME (2017) Diagnosis and treatment of pituitary adenomas: a review. JAMA 317:516–524. https://doi.org/10.1001/jama.2016.19699CrossRefPubMed

Raverot G, Burman P, McCormack A et al (2018) European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1–G24. https://doi.org/10.1530/EJE-17-0796CrossRefPubMed

Raverot G, Dantony E, Beauvy J et al (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102:3368–3374. https://doi.org/10.1210/jc.2017-00773CrossRefPubMed

Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026. https://doi.org/10.1056/NEJMoa1613683CrossRefPubMedPubMedCentral

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774CrossRefPubMed

Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532. https://doi.org/10.1056/NEJMoa1503093CrossRefPubMed

Herbst RS, Baas P, Kim D-W et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7CrossRefPubMed

10.

Lin AL, Jonsson P, Tabar V et al (2018) Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103:3925–3930. https://doi.org/10.1210/jc.2018-01347CrossRefPubMedPubMedCentral

11.

Eigentler TK, Hassel JC, Berking C et al (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7–18. https://doi.org/10.1016/j.ctrv.2016.02.003CrossRefPubMed

12.

Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19:82–92. https://doi.org/10.1007/s11102-015-0671-4CrossRefPubMed

13.

Solinas C, Porcu M, De Silva P et al (2018) Cancer immunotherapy-associated hypophysitis. Semin Oncol 45:181–186. https://doi.org/10.1053/j.seminoncol.2018.09.002CrossRefPubMed

14.

Torino F, Barnabei A, Paragliola RM et al (2013) Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol 169:R153–R164. https://doi.org/10.1530/EJE-13-0434CrossRefPubMed

15.

Mei Y, Bi WL, Greenwald NF et al (2016) Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7:76565–76576. https://doi.org/10.18632/oncotarget.12088CrossRefPubMedPubMedCentral

16.

Salomon MP, Wang X, Marzese DM et al (2018) The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing’s disease and endocrine-inactive subtypes. Clin Cancer Res 24:4126–4136. https://doi.org/10.1158/1078-0432.CCR-17-2206CrossRefPubMed

17.

Wang P, Wang T, Yang Y et al (2018) The expression profile of PD-L1 and CD8 + lymphocyte in pituitary adenomas indicating for immunotherapy. J Neurooncol 139:89–95. https://doi.org/10.1007/s11060-018-2844-2CrossRefPubMed

18.

Sato M, Tamura R, Tamura H et al (2019) Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors. J Clin Med. https://doi.org/10.3390/jcm8050695CrossRefPubMedPubMedCentral

19.

Kemeny HR, Elsamadicy AA, Farber SH et al (2019) Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing’s Disease. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-3486CrossRefPubMedPubMedCentral

20.

Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758–766. https://doi.org/10.1016/j.humpath.2007.10.004CrossRefPubMed

21.

Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134:521–535. https://doi.org/10.1007/s00401-017-1769-8CrossRefPubMed

22.

Saeger W, Honegger J, Theodoropoulou M et al (2016) Clinical impact of the current WHO classification of pituitary adenomas. Endocr Pathol 27:104–114. https://doi.org/10.1007/s12022-016-9418-7CrossRefPubMed

23.

Büttner R, Gosney JR, Skov BG et al (2017) Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 35:3867–3876. https://doi.org/10.1200/JCO.2017.74.7642CrossRefPubMed

24.

Taube JM, Anders RA, Young GD et al (2012) Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. https://doi.org/10.1126/scitranslmed.3003689CrossRefPubMedPubMedCentral

25.

Teng MWL, Ngiow SF, Ribas A, Smyth MJ (2015) Classifying cancers based on T cell infiltration and PD-L1. Cancer Res 75:2139–2145. https://doi.org/10.1158/0008-5472.CAN-15-0255CrossRefPubMedPubMedCentral

26.

Patel KR, Martinez A, Stahl JM et al (2018) Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. Oncoimmunology. https://doi.org/10.1080/2162402X.2018.1442168CrossRefPubMedPubMedCentral

27.

Scheel AH, Baenfer G, Baretton G et al (2018) Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 72:449–459. https://doi.org/10.1111/his.13375CrossRefPubMed

Title: Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
Authors: Valentine Suteau
Alexandre Collin
Philippe Menei
Patrice Rodien
Marie-Christine Rousselet
Claire Briet
Publication date: 01-10-2020
Publisher: Springer Berlin Heidelberg
Keyword: Neuroendocrine Tumor
Published in: Cancer Immunology, Immunotherapy / Issue 10/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02611-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2020

Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer

Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report

Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy

Sex differences in the association between tumor growth and T cell response in a melanoma mouse model

Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions

Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer